Introduction:
Severe sepsis affects approximately 750,000 people in the USA annually, is increasing in incidence, and causes an estimated ICU mortality of 30% (1). Talactoferrin is an orally administered dendritic cell recruiter and activator with gut barrier protection properties as demonstrated by a reduction in indomethacin-mediated gut permeability (2).
Methods:
In this multicenter, randomized, placebo-controlled double blind study, patients with severe sepsis (N=190) were randomized to receive talactoferrin 1.5 g or placebo every eight hours for up to 28 days. The primary endpoint was 28 day all cause mortality. A sample size of 95 patients per arm in this exploratory study provided 80% power to detect a ≥43% reduction in 28-day mortality (from 30% to 17% ) in the talactoferrin-arm with a 1-sided α of <0.1. Patients were stratified by clinical site and by the presence or absence of cardiovascular dysfunction (hypotension refractory to ≥ 20 ml/kg crystalloid administration). Eligible patients had onset of severe sepsis within 24 hours prior to randomization. All potentially eligible patients were centrally screened prior to randomization. The quality control process during the conduct of the trial identified errors in drug labeling and randomization that altered drug assignment for some patients. Results as to the primary endpoint were therefore analyzed using logistic regression in a modified intent-to-treat (MITT) population using "as treated" instead of "as randomized" for group assignment. The labeling errors were random and did not effect blinding. A sensitivity analysis taking into account the labeling errors was conducted and supported the findings in the MITT analysis.
Results:
The baseline characteristics were similar in both groups. The incidence of grade 3 to 5 adverse events was similar in both groups.
Conclusions:
Using a MITT analysis, talactoferrin reduced 28 day mortality in patients with severe sepsis and met the a priori mortality reduction target per protocol. It was very well tolerated. Further study of talactoferrin is warranted in patients with severe sepsis. The study was funded in part by a grant from the National Institutes of Health 4R44GM077816-02
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